"Rapamycin can't reach the brain" is one of the most repeated claims in longevity circles, and a new review says it rests on the wrong measurement. The drug is rarely detectable in cerebrospinal fluid, but the authors explain why that doesn't mean it stays out of brain tissue. Human glioblastoma samples, seizure control in tuberous sclerosis, PET scans in Alzheimer's, and blood flow in APOE4 carriers all point to real activity in the brain. The big catch is that nobody has directly measured the drug in healthy human brain tissue at therapeutic doses. Here's what the evidence supports, what it doesn't, and who should think twice.
This page is available in